Previous reports suggest that melatonin may play an important role in visceral nociception and neurogenic inflammation. We aimed to examine the role of melatonin on visceral hypersensitivity and to explore the site of action using a rat model of post-inflammatory visceral hyperalgesia. In all rats, a baseline viscero-motor response (VMR) to graded colorectal distension (CRD; 10-60 mmHg) was recorded prior and 1 week following tri-nitrobenzenesulfonic acid (TNBS) induced colonic inflammation. Melatonin (30, 45 or 60 mg/kg, ip) was given 20 min before testing the VMR in naïve and TNBS-treated rats. Extracellular single-unit recordings were made from CRD-sensitive pelvic nerve afferent (PNA) fibers and lumbosacral (LS) spinal neurons in TNBS-treated animals. The effect of melatonin (60 mg/kg) was examined on responses of PNAs and spinal neurons to graded CRD. In separate experiments, luzindole (non-specific MT 1 /MT 2 receptor antagonist) or naltrexone (non-specific opiod receptor antagonist) was injected prior to melatonin. Following TNBS, there was a significant increase in the VMR to CRD compared to baseline. This increase was attenuated by melatonin (60 mg/kg) at pressures >20 mmHg. The same dose of melatonin had no effect on the VMR in naïve animals. In TNBS-treated rats, melatonin significantly attenuated the responses of CRD-sensitive spinal neurons to CRD, but had no effect in spinal transected rats or PNA fibers. Both luzindole and naltrexone blocked melatonin's effect on the VMR and LS spinal neurons. Results indicate melatonin's antinociceptive effects are not via a peripheral site of action but rather a supra-spinal process linked to the central opioidergic system. Ó
Introduction
Melatonin, (N-acetyl-5-methoxytryptamine) a derivative of serotonin (5-HT), is a neurohormone that is primarily produced by the pineal gland. It has been implicated in the control of the wake-sleep cycle [18] and also motility of the gastrointestinal tract [6] . In fact, a large source of endogenous melatonin comes from the gastrointestinal tract [4] . Recently, evidence has been mounting to support the role of melatonin in pain regulation [7, 29] . Several studies have suggested that receptors for melatonin (MT 1 and MT 2 ) are expressed throughout the nervous system including the thalamus, hypothalamus, anterior pituitary, and in the dorsal horn of the spinal cord where they are believed to be involved in nociceptive transmission [20] . While the MT 1 and MT 2 receptors appear to play an important role in sleep, their interactions with other systems including the serotonergic, dopaminergic, adrenergic or opioidergic pathways have been proposed as potential mechanisms involved in mediating the antinociceptive effects of melatonin [13] .
Clinical studies in humans have also documented the benefit of melatonin in improving pain in conditions such as irritable bowel syndrome (IBS), fibromyalgia. and migraine headaches [12, 21, 24, 27] . In fact, melatonin has been shown to be superior to placebo in decreasing abdominal pain and extracolonic symptoms in IBS patients as well as improving symptoms of functional dyspepsia [24] . While it has been suggested that melatonin has anti-inflammatory properties, it is unlikely that the antinociceptive effect is through this mechanism alone [5] .
To date, the precise mechanisms through which melatonin attenuates hypersensitivity is not well understood. Multiple studies have demonstrated the antinociceptive effect of melatonin in animal models of acute, inflammatory, and neuropathic pain [1, 7, 29] . While some studies have shown than melatonin significantly decreases spinal dorsal horn neuron firing following stimulation of C 
